{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T15:13:21Z","timestamp":1785510801682,"version":"3.56.0"},"reference-count":28,"publisher":"Akademiai Kiado Zrt.","issue":"8","license":[{"start":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T00:00:00Z","timestamp":1771718400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.akjournals.com"],"crossmark-restriction":true},"short-container-title":["OH"],"published-print":{"date-parts":[[2026,2,22]]},"abstract":"<jats:p>A gyullad\u00e1sos b\u00e9lbetegs\u00e9gek kezel\u00e9s\u00e9ben a biol\u00f3giai ter\u00e1pi\u00e1k forradalmi v\u00e1ltoz\u00e1st\n                    hoztak, lehet\u0151v\u00e9 t\u00e9ve a ny\u00e1lkah\u00e1rtyaszint\u0171 gy\u00f3gyul\u00e1st \u00e9s a tart\u00f3s remisszi\u00f3t. E\n                    k\u00e9sz\u00edtm\u00e9nyek hat\u00e9konys\u00e1g\u00e1t azonban jelent\u0151sen korl\u00e1tozza az immunogenit\u00e1s,\n                    vagyis a gy\u00f3gyszerellenes antitestek k\u00e9pz\u0151d\u00e9se, amely hat\u00e1sveszt\u00e9shez vezethet.\n                    Vizsg\u00e1latunk c\u00e9lja a hazai m\u00e9r\u00e9si eredm\u00e9nyek \u00e1ttekint\u00e9se volt\n                    tumornekr\u00f3zisfaktor-g\u00e1tl\u00f3 infliximab (IFX)- \u00e9s adalimumab (ADA)-, valamint\n                    m\u00e1sodvonalbeli vedolizumab (VDZ)- \u00e9s ustekinumab (UST)-ter\u00e1pia mellett. A 2020\n                    \u00e9s 2025 k\u00f6z\u00f6tt a Semmelweis Egyetemen gondozott 153 (IFX\/ADA), valamint 183\n                    (UST\/VDZ) gyermek \u00e9s feln\u0151tt, gyullad\u00e1sos b\u00e9lbetegs\u00e9gben szenved\u0151 beteg adatait\n                    elemezt\u00fck a k\u00e9t ter\u00e1pi\u00e1s csoportban. Az elemz\u00e9s sor\u00e1n a keresztmetszeti\n                    adatgy\u0171jt\u00e9s m\u00f3dszer\u00e9t alkalmaztuk, kieg\u00e9sz\u00edtve a leg\u00fajabb immunoassay-technik\u00e1k\n                    \u00e1ltal szolg\u00e1ltatott adatokkal. A teljes popul\u00e1ci\u00f3ban az antitestk\u00e9pz\u0151d\u00e9s ar\u00e1nya\n                    a k\u00e9t kezel\u00e9si csoportban 21% \u00e9s 20% volt (IFX\/ADA: 32\/153; USTE\/VDZ: 37\/181; p\n                    = 0,98). A ter\u00e1pi\u00e1k k\u00f6z\u00f6tti \u00f6sszehasonl\u00edt\u00e1sban az IFX mellett nagyobb\n                    immunogenit\u00e1s volt megfigyelhet\u0151 (33,0%), amely meghaladta az ADA eset\u00e9ben\n                    tapasztalt \u00e9rt\u00e9ket (12,0%; p = 0,001). Az antitest-pozitivit\u00e1s UST mellett\n                    alacsony (15,0%), m\u00edg VDZ mellett nem szignifik\u00e1nsan, de nagyobb ar\u00e1ny volt\n                    m\u00e9rhet\u0151 (28,0%; p = 0,105). A gyullad\u00e1sos b\u00e9lbetegs\u00e9g t\u00edpusa, az \u00e9letkor \u00e9s a\n                    nem szerint egyik ter\u00e1piacsoportban sem volt kimutathat\u00f3 k\u00fcl\u00f6nbs\u00e9g az\n                    antitestk\u00e9pz\u0151d\u00e9s gyakoris\u00e1g\u00e1ban. Eredm\u00e9nyeink r\u00e1mutatnak, hogy b\u00e1r a biol\u00f3giai\n                    szerek \u00e1tlagos immunogenit\u00e1sa hasonl\u00f3 lehet, az egyes molekul\u00e1k k\u00f6z\u00f6tt jelent\u0151s\n                    elt\u00e9r\u00e9sek vannak. Az IFX nagy immunogenit\u00e1sa, szemben az ADA alacsonyabb\n                    \u00e9rt\u00e9k\u00e9vel, indokolja a szoros proakt\u00edv monitoroz\u00e1st \u00e9s a kombin\u00e1ci\u00f3s kezel\u00e9st. A\n                    VDZ \u00e9s az UST eset\u00e9ben az eredm\u00e9nyek \u00e1rnyaltabb megk\u00f6zel\u00edt\u00e9st ig\u00e9nyelnek,\n                    figyelembe v\u00e9ve az esetleges tranzitorikus antitestek jelenl\u00e9t\u00e9t. A vizsg\u00e1lat\n                    al\u00e1t\u00e1masztja a ter\u00e1pi\u00e1s gy\u00f3gyszerszint-monitoroz\u00e1s kiemelt szerep\u00e9t a ter\u00e1pia\n                    optimaliz\u00e1l\u00e1s\u00e1ban. Orv Hetil. 2026; 167(8): 291\u2013299.<\/jats:p>","DOI":"10.1556\/650.2026.33493","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T08:06:17Z","timestamp":1771833977000},"page":"291-299","update-policy":"https:\/\/doi.org\/10.1556\/policypage.crossmark.crossref.2","source":"Crossref","is-referenced-by-count":1,"title":["Az antitestk\u00e9pz\u0151d\u00e9s gyakoris\u00e1ga biol\u00f3giai ter\u00e1pi\u00e1k sor\u00e1n gyullad\u00e1sos b\u00e9lbetegs\u00e9gekben"],"prefix":"10.1556","volume":"167","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-5193-927X","authenticated-orcid":true,"given":"Kriszti\u00e1n","family":"Kov\u00e1cs","sequence":"first","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Laborat\u00f3riumi Medicina Int\u00e9zet Budapest, Nagyv\u00e1rad t\u00e9r 4., 14. emelet, 1089; Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Nagyp\u00e1l","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Gyermekgy\u00f3gy\u00e1szati Klinika Budapest Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barna","family":"V\u00e1s\u00e1rhelyi","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Laborat\u00f3riumi Medicina Int\u00e9zet Budapest, Nagyv\u00e1rad t\u00e9r 4., 14. emelet, 1089; Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antal","family":"Dezs\u0151fi-Gottl","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Gyermekgy\u00f3gy\u00e1szati Klinika Budapest Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N\u00f3ra Judit","family":"B\u00e9res","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Gyermekgy\u00f3gy\u00e1szati Klinika Budapest Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e1l","family":"Miheller","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Seb\u00e9szeti, Transzplant\u00e1ci\u00f3s \u00e9s Gasztroenterol\u00f3giai Klinika Budapest Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1kos","family":"Ili\u00e1s","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Belgy\u00f3gy\u00e1szati \u00e9s Onkol\u00f3giai Klinika Budapest Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Balogh","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Gyermekgy\u00f3gy\u00e1szati Klinika Budapest Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bence","family":"Prehoda","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Gyermekgy\u00f3gy\u00e1szati Klinika Budapest Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"T\u00f3bi","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Gyermekgy\u00f3gy\u00e1szati Klinika Budapest Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attila","family":"Szab\u00f3","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Gyermekgy\u00f3gy\u00e1szati Klinika Budapest Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ron","family":"Cseh","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Gyermekgy\u00f3gy\u00e1szati Klinika Budapest Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"425","reference":[{"key":"R1","doi-asserted-by":"crossref","unstructured":"Vermeire S, Gils A, Accossato P, et al. Immunogenicity of biologics\n                    in inflammatory bowel disease. Therap Adv Gastroenterol. 2018; 11:\n                    11756283X17750355.\n                    https:\/\/doi.org\/10.1177\/1756283X17750355","DOI":"10.1177\/1756283X17750355"},{"key":"R2","doi-asserted-by":"crossref","unstructured":"Feagan BG, Sandborn WJ, Gasink C, et al. Ustekinumab as induction\n                    and maintenance therapy for Crohn\u2019s disease. N Engl J Med. 2016; 375: 1946-1960.\n                        https:\/\/doi.org\/10.1056\/NEJMoa1602773","DOI":"10.1056\/NEJMoa1602773"},{"key":"R3","doi-asserted-by":"crossref","unstructured":"Farkas K, Sz\u00e9kely H, Bacsur P, et al. Therapeutic strategy of\n                    Crohn-disease. [A Crohn-betegs\u00e9g ter\u00e1pi\u00e1s strat\u00e9gi\u00e1ja.] Orv Hetil. 2024;\n                    165(Suppl 1): 1-36. [Hungarian]\n                        https:\/\/doi.org\/10.1556\/650.2024.33020","DOI":"10.1556\/650.2024.33020"},{"key":"R4","doi-asserted-by":"crossref","unstructured":"Gisbert JP, Chaparro M. Predictors of primary response to biologic\n                    treatment [anti-TNF, vedolizumab, and ustekinumab] in patients with inflammatory\n                    bowel disease: from basic science to clinical practice. J Crohns Colitis 2020;\n                    14(5): 694-709.\n                    https:\/\/doi.org\/10.1093\/ecco-jcc\/jjz195","DOI":"10.1093\/ecco-jcc\/jjz195"},{"key":"R5","doi-asserted-by":"crossref","unstructured":"Costable NJ, Borman ZA, Ji J, et al. Prior immunogenicity to\n                    anti-TNF biologics is not associated with increased anti-drug antibodies to\n                    vedolizumab or ustekinumab. Dig Dis Sci. 2022; 67: 2480-2484.\n                        https:\/\/doi.org\/10.1007\/s10620-021-07046-7","DOI":"10.1007\/s10620-021-07046-7"},{"key":"R6","doi-asserted-by":"crossref","unstructured":"Papamichael K, Afif W, Drobne D, et al. Therapeutic drug monitoring\n                    of biologics in inflammatory bowel disease: unmet needs and future perspectives.\n                    Lancet Gastroenterol Hepatol 2022; 7(2): 171-185.\n                        https:\/\/doi.org\/10.1016\/S2468-1253(21)00223-5","DOI":"10.1016\/S2468-1253(21)00223-5"},{"key":"R7","doi-asserted-by":"crossref","unstructured":"Sazonovs A, Kennedy NA, Moutsianas L, Heap GA, Rice DL, Reppell M,\n                    et al. HLA-DQA1*05 carriage associated with development of anti-drug antibodies\n                    to infliximab and adalimumab in patients with Crohn\u2019s disease. Gastroenterology.\n                    2020; 158: 189-199.\n                    https:\/\/doi.org\/10.1053\/j.gastro.2019.09.041","DOI":"10.1053\/j.gastro.2019.09.041"},{"key":"R8","doi-asserted-by":"crossref","unstructured":"Baert F, Noman M, Vermeire S, et al. Influence of immunegenicity on\n                    the long-term efficacy of infliximab in Crohn\u2019s disease. N Engl J Med. 2003;\n                    348: 601-608. https:\/\/doi.org\/10.1056\/NEJMoa020888","DOI":"10.1056\/NEJMoa020888"},{"key":"R9","unstructured":"Ungar B, Kopylov U, Yavzori M, et al. Prospective observational\n                    evaluation of adalimumab immunogenicity, drug levels and clinical response in\n                    IBD. Aliment Pharmacol Ther. 2014; 40: 943-953."},{"key":"R10","doi-asserted-by":"crossref","unstructured":"Williet N, Boschetti G, Fovet M, et al. Association between low\n                    trough levels of vedolizumab during induction therapy for inflammatory bowel\n                    diseases and need for additional doses within 6 months. Clin Gastroenterol\n                    Hepatol. 2017; 15: 1750-1757.\n                        https:\/\/doi.org\/10.1016\/j.cgh.2016.11.023","DOI":"10.1016\/j.cgh.2016.11.023"},{"key":"R11","doi-asserted-by":"crossref","unstructured":"Wyant T, Yang L, Lirio RA, et al. Vedolizumab immunogenicity with\n                    long-term or interrupted treatment of patients with inflammatory bowel disease.\n                    J Clin Pharmacol. 2021; 61: 1174-1181.\n                        https:\/\/doi.org\/10.1002\/jcph.1877","DOI":"10.1002\/jcph.1877"},{"key":"R12","doi-asserted-by":"crossref","unstructured":"Sands BE, Peyrin-Biroulet L, Kierkus J, Efficacy and safety of\n                    mirikizumab in a randomized phase 2 study of patients with Crohn\u2019s disease.\n                    Gastroenterology 2022; 162: 495-508.\n                        https:\/\/doi.org\/10.1053\/j.gastro.2021.10.050","DOI":"10.1053\/j.gastro.2021.10.050"},{"key":"R13","doi-asserted-by":"crossref","unstructured":"Roblin X, Duru G, Papamichael K, et al. Development of antibodies to\n                    ustekinumab is associated with loss of response in patients with inflammatory\n                    bowel disease. J Clin Med. 2023; 12: 3395.\n                        https:\/\/doi.org\/10.3390\/jcm12103395","DOI":"10.3390\/jcm12103395"},{"key":"R14","doi-asserted-by":"crossref","unstructured":"Farkas B, Bacsur P, Iv\u00e1ny E, et al. Therapeutic challenges in\n                    difficult-to-treat, penetrating Crohn\u2019s disease - a multidisciplinary approach.\n                    [Ter\u00e1pi\u00e1s kih\u00edv\u00e1sok nehezen kezelhet\u0151, penetr\u00e1l\u00f3 Crohn-betegs\u00e9gben -\n                    multidiszciplin\u00e1ris megold\u00e1s.] Orv Hetil. 2024; 165: 1252-1257. [Hungarian]\n                        https:\/\/doi.org\/10.1556\/650.2024.33105","DOI":"10.1556\/650.2024.33105"},{"key":"R15","doi-asserted-by":"crossref","unstructured":"Corica D, Romano C. Biological therapy in pediatric inflammatory\n                    bowel disease: a systematic review. J Clin Gastroenterol. 2017; 51: 100-110.\n                        https:\/\/doi.org\/10.1097\/MCG.0000000000000696","DOI":"10.1097\/MCG.0000000000000696"},{"key":"R16","unstructured":"Pinto Pais I, Espinheira MC. Inflammatory bowel disease in pediatric\n                    patients: current therapy and future perspectives. GE Port J Gastroenterol.\n                    2019; 26: 268-279."},{"key":"R17","doi-asserted-by":"crossref","unstructured":"Mitrev N, Vande Casteele N, Seow CH, et al. Review article:\n                    consensus statements on therapeutic drug monitoring of anti-tumour necrosis\n                    factor therapy in inflammatory bowel diseases. Aliment Pharmacol Ther. 2017;\n                    46(11-12): 1037-1053.\n                    https:\/\/doi.org\/10.1111\/apt.14368","DOI":"10.1111\/apt.14368"},{"key":"R18","doi-asserted-by":"crossref","unstructured":"Assa A, Matar M, Turner D, et al. Proactive monitoring of adalimumab\n                    trough concentration associated with increased clinical remission in children\n                    with Crohn\u2019s disease compared with reactive monitoring. Gastroenterology 2019;\n                    157: 985-996. e2.\n                    https:\/\/doi.org\/10.1053\/j.gastro.2019.06.003","DOI":"10.1053\/j.gastro.2019.06.003"},{"key":"R19","doi-asserted-by":"crossref","unstructured":"Steenholdt C, Brynskov J, Thomsen O\u00d8, et al. Individualised therapy\n                    is more cost-effective than dose intensification in patients with Crohn\u2019s\n                    disease who lose response to anti-TNF treatment: a randomized controlled trial.\n                    Gut 2014; 63: 919-927.\n                    https:\/\/doi.org\/10.1136\/gutjnl-2013-305279","DOI":"10.1136\/gutjnl-2013-305279"},{"key":"R20","doi-asserted-by":"crossref","unstructured":"Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab,\n                    azathioprine, or combination therapy for Crohn\u2019s disease. N Engl J Med. 2010;\n                    362: 1383-1395.\n                    https:\/\/doi.org\/10.1056\/NEJMoa0904492","DOI":"10.1056\/NEJMoa0904492"},{"key":"R21","doi-asserted-by":"crossref","unstructured":"de Ridder L, Assa A, Bronsky J, et al. Use of biosimilars in\n                    pediatric inflammatory bowel disease: an updated position statement of the\n                    Pediatric IBD Porto Group of ESPGHAN. J Pediatr Gastroenterol Nutr. 2019; 68:\n                    144-153.\n                    https:\/\/doi.org\/10.1097\/MPG.0000000000002141","DOI":"10.1097\/MPG.0000000000002141"},{"key":"R22","unstructured":"BioSynex Theradiag. Lisa Tracker. Available from:\n                        https:\/\/www.theradiag.com\/theranostic\/tracker\/lisa-tracker\n                    [accessed: 10 December 2015]."},{"key":"R23","doi-asserted-by":"crossref","unstructured":"Kov\u00e1cs K, Nagyp\u00e1l P, V\u00e1s\u00e1rhelyi B, et al. Interaction of clinical\n                    factors modestly predict anti-TNF-alpha antibody formation in a real-world\n                    cohort of inflammatory bowel disease patients. Biomedicines 2025; 13: 2622.\n                        https:\/\/doi.org\/10.3390\/biomedicines13112622","DOI":"10.3390\/biomedicines13112622"},{"key":"R24","doi-asserted-by":"crossref","unstructured":"Kennedy NA, Heap GA, Green HD, et al. Predictors of anti-TNF\n                    treatment failure in anti-TNF-naive patients with active luminal Crohn\u2019s\n                    disease: a prospective, multicentre, cohort study. Lancet Gastroenterol Hepatol.\n                    2019; 4: 341-353.\n                    https:\/\/doi.org\/10.1016\/S2468-1253(19)30012-3","DOI":"10.1016\/S2468-1253(19)30012-3"},{"key":"R25","doi-asserted-by":"crossref","unstructured":"Williet N, Boschetti G, Fovet M, et al. Vedolizumab trough levels\n                    and antidrug antibodies are associated with therapeutic response in inflammatory\n                    bowel diseases. Clin Gastroenterol Hepatol. 2017; 15: 753-761.","DOI":"10.1016\/j.cgh.2016.11.023"},{"key":"R26","doi-asserted-by":"crossref","unstructured":"Solitano V, Vuyyuru SK, MacDonald JK, et al. Efficacy and safety of\n                    advanced oral small molecules for inflammatory bowel disease: systematic review\n                    and meta-analysis. J Crohns Colitis 2023; 17: 1800-1816.\n                        https:\/\/doi.org\/10.1093\/ecco-jcc\/jjad100","DOI":"10.1093\/ecco-jcc\/jjad100"},{"key":"R27","doi-asserted-by":"crossref","unstructured":"Vande Casteele N, Ferrante M, Van Assche G, et al. Trough\n                    concentrations of infliximab guide dosing for patients with inflammatory bowel\n                    disease. Gastroenterology 2015; 148: 1320-1329. e3.\n                        https:\/\/doi.org\/10.1053\/j.gastro.2015.02.031","DOI":"10.1053\/j.gastro.2015.02.031"},{"key":"R28","doi-asserted-by":"crossref","unstructured":"T\u00f3bi L, Cseh \u00c1. The characteristics of pediatric-onset inflammatory\n                    bowel disease based on our 20-year-long study. [A gyermekkorban kezd\u0151d\u0151\n                    gyullad\u00e1sos b\u00e9lbetegs\u00e9g saj\u00e1toss\u00e1gai 20 \u00e9ves tapasztalatunk alapj\u00e1n.] Orv Hetil.\n                    2025; 166: 403-412. [Hungarian]\n                        https:\/\/doi.org\/10.1556\/650.2025.33249","DOI":"10.1556\/650.2025.33249"}],"container-title":["Orvosi Hetilap"],"original-title":[],"link":[{"URL":"https:\/\/www.akjournals.com\/view\/journals\/650\/167\/8\/article-p291.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.akjournals.com\/downloadpdf\/journals\/650\/167\/8\/article-p291.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/www.akjournals.com\/downloadpdf\/journals\/650\/167\/8\/article-p291.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T14:46:50Z","timestamp":1785509210000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.akjournals.com\/view\/journals\/650\/167\/8\/article-p291.xml"}},"subtitle":["Saj\u00e1t adatokkal illusztr\u00e1lva"],"short-title":[],"issued":{"date-parts":[[2026,2,22]]},"references-count":28,"journal-issue":{"issue":"8"},"URL":"https:\/\/doi.org\/10.1556\/650.2026.33493","relation":{},"ISSN":["0030-6002","1788-6120"],"issn-type":[{"value":"0030-6002","type":"print"},{"value":"1788-6120","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,22]]}}}